Governance Bright Minds Biosciences Inc.

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:49:39 05/06/2026 BST			5-day change	1st Jan Change
96.12 ^CAD	-6.38%		-21.71%	-12.96%

05-19	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-08	Certain RSUs of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026.	CI

Executive Committee: Bright Minds Biosciences Inc.

Manager

Positions heldSince

Ian McDonald

38 year

Chief Executive Officer	04/06/2020
Founder	30/05/2019
President	30/05/2019

Stephen D. Collins

Chief Tech/Sci/R&D Officer

06/01/2025

Ryan Cheung

47 year

Director of Finance/CFO	28/05/2020
Corporate Secretary	-

Jan Pedersen

61 year

Chief Tech/Sci/R&D Officer

26/06/2022

Alex Vasilkevich

Chief Operating Officer	31/05/2024
Public Communications Contact	-

Composition of the Board of Directors: Bright Minds Biosciences Inc.

Director

CommitteesSince

Nils Bottler

38 year

Audit Committee Chair	28/09/2020
Compensation Committee Chair	28/09/2020
Governance Committee Chair	28/09/2020
Nominating Committee Chair	28/09/2020

Jeremy Fryzuk

40 year

Audit Committee	28/09/2020
Compensation Committee	28/09/2020
Governance Committee	28/09/2020
Nominating Committee	28/09/2020

David Weiner

61 year

Audit Committee	16/02/2023
Compensation Committee	16/02/2023
Governance Committee	16/02/2023
Nominating Committee

Jan Pedersen

61 year

Director/Board Member

31/03/2022

Ian McDonald

38 year

Director/Board Member

30/05/2019

Latest Appointments: Bright Minds Biosciences Inc.

11-17	Bright Minds Biosciences Inc. Expands Scientific Advisory Board	CI
04/03/25	Bright Minds Biosciences Inc. Expands Scientific Advisory Board	CI
07/01/25	Bright Minds Biosciences Announces Chief Medical Officer Changes	CI
17/02/23	Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director	CI
08/02/23	Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee	CI
09/01/23	Bright Minds Biosciences Inc. Announces the Resignation of Doug Williamson from Board of Directors	CI
23/11/22	Bright Minds Biosciences Names Mark Smith Chief Medical Officer	MT

More news

Former Officers and Directors: Bright Minds Biosciences Inc.

Insider

Positions held

SinceUntil

Mark Smith

Chief Tech/Sci/R&D Officer

30/11/2022

06/01/2025

Douglas Williamson

Director/Board Member	06/09/2022	08/01/2023
Independent Dir/Board Member	06/09/2022	08/01/2023

Revati Shreeniwas

Chief Tech/Sci/R&D Officer

04/06/2020

30/11/2022

Alan Kozikowski

Director/Board Member	30/05/2019	06/09/2022
Chief Tech/Sci/R&D Officer	28/10/2020	26/06/2022
Founder	30/05/2019	06/09/2022

Emer Leahy

Director/Board Member	09/06/2021	24/04/2022
Independent Dir/Board Member	09/06/2021	24/04/2022

Thomas Lategan

General Counsel

13/06/2021

Gideon Shapiro

Corporate Officer/Principal

28/09/2020

Age distribution of managers

Parity Men Women

Male	9
Female	0

Of which Executive Committee

Male	5
Female	0

Of which Directors

Male	5
Female	0

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Employees

Sector

Biotechnology & Medical Research

More about the company